NEW YORK (GenomeWeb News) – Kindstar Global will validate and implement Advanced Cell Diagnostics' RNAscope technology-based molecular diagnostic assays as part of a partnership the firms announced today.

The firms said that the deal will allow Kindstar to leverage ACD's RNA biomarker analysis platform to offer new cancer diagnostic tests to the 3,300-plus hospitals in Kindstar's network in China.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In Science this week: the Human Silencing Hub protein complex, and more.

Heads of various research funding agencies discuss how to encourage scientific breakthroughs, ScienceInsider reports.

The Kansas City Star examines issues surrounding newborn genome sequencing.

Researchers say their Research Resource Identifier citation format is catching on, Nature News reports.